173 related articles for article (PubMed ID: 31924504)
21. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
[TBL] [Abstract][Full Text] [Related]
23. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.
Cheng J; Qin J; Guo S; Qiu H; Zhong Y
Bioorg Med Chem Lett; 2014 Oct; 24(19):4768-4772. PubMed ID: 25182565
[TBL] [Abstract][Full Text] [Related]
26. Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines.
Nencetti S; Cuffaro D; Nuti E; Ciccone L; Rossello A; Fabbi M; Ballante F; Ortore G; Carbotti G; Campelli F; Banti I; Gangemi R; Marshall GR; Orlandini E
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):34-47. PubMed ID: 33100043
[TBL] [Abstract][Full Text] [Related]
27. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
[TBL] [Abstract][Full Text] [Related]
28. Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine.
Tretbar M; Schliehe-Diecks J; von Bredow L; Tan K; Roatsch M; Tu JW; Kemkes M; Sönnichsen M; Schöler A; Borkhardt A; Bhatia S; Hansen FK
Eur J Med Chem; 2024 Jun; 272():116447. PubMed ID: 38714044
[TBL] [Abstract][Full Text] [Related]
29. Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs).
Linciano P; Benedetti R; Pinzi L; Russo F; Chianese U; Sorbi C; Altucci L; Rastelli G; Brasili L; Franchini S
Bioorg Chem; 2021 Jan; 106():104462. PubMed ID: 33213894
[TBL] [Abstract][Full Text] [Related]
30. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
32. 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
Valente S; Trisciuoglio D; De Luca T; Nebbioso A; Labella D; Lenoci A; Bigogno C; Dondio G; Miceli M; Brosch G; Del Bufalo D; Altucci L; Mai A
J Med Chem; 2014 Jul; 57(14):6259-65. PubMed ID: 24972008
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities.
Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS
Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
[TBL] [Abstract][Full Text] [Related]
35. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
36. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
Yao Y; Liao C; Li Z; Wang Z; Sun Q; Liu C; Yang Y; Tu Z; Jiang S
Eur J Med Chem; 2014 Oct; 86():639-52. PubMed ID: 25218912
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors.
Dong Y; Hu H; Sun Y; Qin M; Gong P; Hou Y; Zhao Y
Bioorg Med Chem Lett; 2020 Dec; 30(23):127610. PubMed ID: 33045329
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Liang T; Xue J; Yao Z; Ye Y; Yang X; Hou X; Fang H
Eur J Med Chem; 2021 Oct; 221():113526. PubMed ID: 33992929
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Xie R; Li Y; Tang P; Yuan Q
Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
